Feasibility and Stability of Liver Biopsy before Treatment for Preclinical Nonalcoholic Fatty Liver Studies

다국어 초록 (Multilingual Abstract)

Background: The heterogeneity of histological findings in preclinical diet-induced nonalcoholic fatty liver disease (NAFLD) animal models is highly challenging. Here, we aimed to evaluate the feasibility and stability of repeated liver biopsy in NAFLD animal models.
Methods: Heterogeneity of diet-induced NAFLD was evaluated at different time points in 52 high-fat diet (HFD), 35 methionine choline-deficiency diet (MCD), and 166 western diet (WD) induced NAFLD mice. Serial liver biopsies (left lateral, right medial, and left medial lobes) were performed monthly for up to 3 months. Mortality rates and changes in food intake, body weight, and liver enzymes were assessed.
Results: At 12 weeks, of the HFD animals, 14% and 30% did not develop steatosis and lobular inflammation, respectively; of the MCD animals, 7% did not develop lobular inflammation; and of the WD animals, 14% and 51% did not develop steatosis and lobular inflammation, respectively. The mortality rate of repeated liver biopsy was 1.62% (2/123 mice died).
Repeated liver biopsy can be used to trace disease progression. Although body weight, food intake, and liver enzymes slightly changed after biopsy, all recovered within a week. Repeated liver biopsy did not affect the degrees of inflammation and steatosis of the other liver lobes.
Conclusion: The diet-induced NAFLD models were quite heterogeneous. Our results suggest that the repeated liver biopsy before treatment was applicable and stable in this NAFLD animal study.

참고문헌 (Reference)

1 Farrell GC, "Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype" 34 (34): 1084-1093, 2014

2 Santhekadur PK, "Preclinical models of non-alcoholic fatty liver disease" 68 (68): 230-237, 2018

3 Sanyal AJ, "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis" 362 (362): 1675-1685, 2010

4 Haczeyni F, "Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice" 25 (25): 155-165, 2017

5 Kristiansen MN, "Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy" 8 (8): 673-684, 2016

6 Machado MV, "Non-alcoholic fatty liver disease : what the clinician needs to know" 20 (20): 12956-12980, 2014

7 Hansen HH, "Mouse models of nonalcoholic steatohepatitis in preclinical drug development" 22 (22): 1707-1718, 2017

8 Itagaki H, "Morphological and functional characterization of non-alcoholic fatty liver disease induced by a methionine-choline-deficient diet in C57BL/6 mice" 6 (6): 2683-2696, 2013

9 Tessitore A, "MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression : study on C57BL/6J mice" 16 (16): 3-, 2016

10 Tølbøl KS, "Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis" 24 (24): 179-194, 2018

11 Armstrong MJ, "Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis(LEAN) : a multicentre, double-blind, randomised, placebo-controlled phase 2 study" 387 (387): 679-690, 2016

12 Lee JS, "Histologic and metabolic derangement in high-fat, high-fructose, and combination diet animal models" 2015 : 306326-, 2015

13 Mekada K, "Genetic differences among C57BL/6 substrains" 58 (58): 141-149, 2009

14 Neuschwander-Tetri BA, "Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis(FLINT) : a multicentre, randomised, placebo-controlled trial" 385 (385): 956-965, 2015

15 강윤구, "Estimated Prevalence of Adolescents with Nonalcoholic Fatty Liver Disease in Korea" 대한의학회 33 (33): 29-38, 2018

16 Ratziu V, "Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and-delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening" 150 (150): 1147-1159, 2016

17 Clapper JR, "Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment" 305 (305): G483-495, 2013

18 Gallou-Kabani C, "C57BL/6J and A/J mice fed a high-fat diet delineate components of metabolic syndrome" 15 (15): 1996-2005, 2007

19 Lassailly G, "Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients" 149 (149): 379-388, 2015

20 Takahashi Y, "Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis" 18 (18): 2300-2308, 2012

21 Toye AA, "A genetic and physiological study of impaired glucose homeostasis control in C57BL/6J mice" 48 (48): 675-686, 2005